Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Quality of Life Research
Gepubliceerd in: Quality of Life Research 7/2011

01-09-2011

Validation of POMS questionnaire in postmenopausal women

Auteurs: Kathleen W. Wyrwich, Holly Yu

Gepubliceerd in: Quality of Life Research | Uitgave 7/2011

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

To evaluate the psychometric properties of the Profile of Mood States (POMS) in postmenopausal women with moderate to severe vasomotor symptoms.

Methods

Internal consistency, validity, and reliability of the POMS were examined using blinded data from 539 postmenopausal women with ≥50 moderate to severe hot flushes per week at baseline enrolled in a multicenter, randomized, double-blind, placebo-controlled study of the efficacy and safety of desvenlafaxine (administered as desvenlafaxine succinate) for vasomotor symptoms.

Results

The POMS subscales and total score demonstrated sound internal consistency reliability (α ≥ 0.84). Comparisons between POMS subscales and Total Mood Disturbance (TMD) scores with Greene Climacteric Scale domains provided consistent known-groups and construct validity. Results from the confirmatory factor analysis were supportive of the second-order factor structure (root-mean-square error of approximation = 0.078). For women with POMS TMD scores below the US adult female norms, there was little mean change at Week 12 but marked mean improvement in women with greater mood symptoms scoring worse than the norm at baseline.

Conclusion

These data demonstrate the internal consistency and validity of the POMS to measure mood among postmenopausal women with moderate to severe hot flushes and the responsiveness of the POMS among these women with greater mood symptoms.
vorige artikel Erratum to: Fatigue in children: reliability and validity of the Dutch PedsQL™ Multidimensional Fatigue Scale
volgende artikel Quality of life in Brazil: normative values for the Whoqol-bref in a southern general population sample
Literatuur
1.
McNair, D. M., Lorr, M., & Droppleman, L. F. (1992). EDITS manual profile of mood states. San Diego: Educational and Industrial Testing Service.
2.
McNair, D. M., Heuchert, J. W. P., & Shilony, E. (2003). Profile of mood states bibliography 1964–2002. Toronto, Canada: Multi-Health Systems.
3.
Joffe, H., Hall, J. E., Soares, C. N., Hennen, J., Reilly, C. J., Carlson, K., et al. (2002). Vasomotor symptoms are associated with depression in perimenopausal women seeking primary care. Menopause, 9(6), 392–398.PubMedCrossRef
4.
Cohen, L. S., Soares, C. N., Vitonis, A. F., Otto, M. W., & Harlow, B. L. (2006). Risk for new onset of depression during the menopausal transition: The Harvard study of moods and cycles. Archives of General Psychiatry, 63(4), 385–390.PubMedCrossRef
5.
Freeman, E. W., Sammel, M. D., Lin, H., & Nelson, D. B. (2006). Associations of hormones and menopausal status with depressed mood in women with no history of depression. Archives of General Psychiatry, 63(4), 375–382.PubMedCrossRef
6.
Baker, A., Simpson, S., & Dawson, D. (1997). Sleep disruption and mood changes associated with menopause. Journal of Psychosomatic Research, 43(4), 359–369.PubMedCrossRef
7.
Banger, M., Rimpel, J., Lodemann, E., Feldmann, H. U., & Gastpar, M. (1999). Self-assessment of somatic and psychic symptoms during a two months period of hormone replacement therapy in perimenopausal women. Archives of Women’s Mental Health, 1(4), 183–187.CrossRef
8.
Miller, K. J., Conney, J. C., Rasgon, N. L., Fairbanks, L. A., & Small, G. W. (2002). Mood symptoms and cognitive performance in women estrogen users and nonusers and men. Journal of the American Geriatric Society, 50(11), 1826–1830.CrossRef
9.
Cummings, J. A., & Brizendine, L. (2002). Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women. Menopause, 9(4), 253–263.PubMedCrossRef
10.
Barton, D. L., Loprinzi, C. L., Novotny, P., Shanafelt, T., Sloan, J., Wahner-Roedler, D., et al. (2003). Pilot evaluation of citalopram for the relief of hot flashes. Journal of Supportive Oncology, 1(1), 47–51.PubMed
11.
Slaven, L., & Lee, C. (1997). Mood and symptom reporting among middle-aged women: The relationship between menopausal status, hormone replacement therapy, and exercise participation. Health Psychology, 16(3), 203–208.PubMedCrossRef
12.
Irvin, J. H., Domar, A. D., Clark, C., Zuttermeister, P. C., & Friedman, R. (1996). The effects of relaxation response training on menopausal symptoms. Journal of Psychosomatic Obstetrics and Gynaecology, 17(4), 202–207.PubMedCrossRef
13.
Ishiwata, N., Melby, M. K., Mizuno, S., & Watanabe, S. (2009). New equol supplement for relieving menopausal symptoms: Randomized, placebo-controlled trial of Japanese women. Menopause, 16(1), 141–148.PubMedCrossRef
14.
Slaven, L., & Lee, C. (1994). Psychological effects of exercise among adult women: The impact of menopausal status. Psychology & Health, 9(4), 297–303.CrossRef
15.
Allen, S. S., Hatsukami, D. K., & Christianson, D. (2003). Nicotine withdrawal and depressive symptomatology during short-term smoking abstinence: A comparison of postmenopausal women using and not using hormone replacement therapy. Nicotine & Tobacco Research, 5(1), 49–59.CrossRef
16.
Allen, S. S., Hatsukami, D. K., Bade, T., & Center, B. (2004). Transdermal nicotine use in postmenopausal women: Does the treatment efficacy differ in women using and not using hormone replacement therapy? Nicotine & Tobacco Research, 6(5), 777–788.CrossRef
17.
Archer, D. F., Dupont, C. M., Constantine, G. D., Pickar, J. H., & Olivier, S. (2009). Desvenlafaxine for the treatment of vasomotor symptoms associated with menopause: A double-blind, randomized, placebo-controlled trial of efficacy and safety. American Journal of Obstetrics and Gynecology, 200(3), 238e1–238e10.CrossRef
18.
Pristiq [package insert]. (2008). Philadelphia, PA: Wyeth Pharmaceuticals Inc.
19.
Speroff, L., Gass, M., Constantine, G., & Olivier, S. (2008). Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: A randomized controlled trial. Obstetrics and Gynecology, 111(1), 77–87.PubMedCrossRef
20.
Archer, D. F., Seidman, L., Constantine, G. D., Pickar, J. H., & Olivier, S. (2009). A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. American Journal of Obstetrics and Gynecology, 200(2), 172.e1–172.e10.CrossRef
21.
22.
Greene, J. G. (1976). A factor analytic study of climacteric symptoms. Journal of Psychosomatic Research, 20(5), 425–430.PubMedCrossRef
23.
24.
Cunningham, W. E., Hays, R. D., Burton, T. M., & Kington, R. S. (2000). Health status measurement performance and health status differences by age, ethnicity, and gender: Assessment in the medical outcomes study. Journal of Health Care for the Poor and Underserved, 11(1), 58–76.PubMed
25.
Nunnally, J. C., & Bernstein, I. H. (1994). Psychometric theory (3rd ed.). New York, NY: McGraw-Hill.
26.
Streiner, D. L., & Norman, G. R. (Eds.). (2003). Health measurement scales: A practical guide to their development and use (3rd ed.). Oxford: Oxford University Press.
27.
McNair, D. M., Lorr, J., & Droppleman, L. F. (2003). Profile of mood states. Technical update. North Tonawanda, NY: Multi-Health Systems.
28.
Hinkle, D. E., Wiersma, W., & Jurs, S. G. (1988). Applied statistics for the behavioral sciences (2nd ed.). Boston, MA: Houghton Mifflin Company.
29.
30.
31.
Kline, R. B. (2005). Principles and practice of structural equation modeling (2nd ed.). New York, NY: The Guilford Press.
32.
Schriesheim, C. A., Eisenbach, R. J., & Hill, K. D. (1991). The effect of negation and polar opposite item reversals on questionnaire reliability and validity: An experimental investigation. Educational and Psychological Measurement, 51(1), 67–78.CrossRef
33.
Federal Drug Administration. (2009). Guidance for industry on patient-reported outcome measures: Use in medical product development to support labeling claims. Federal Register, 74(235), 65132–65133.
34.
MacLennan, A. H., Broadbent, J. L., Lester, S., & Moore, V. (2004). Oral oestrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database of Systematic Reviews, (4), CD002978.
Metagegevens
Titel
Validation of POMS questionnaire in postmenopausal women
Auteurs
Kathleen W. Wyrwich
Holly Yu
Publicatiedatum
01-09-2011
Uitgeverij
Springer Netherlands
Gepubliceerd in
Quality of Life Research / Uitgave 7/2011
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-011-9846-2

Andere artikelen Uitgave 7/2011

Quality of Life Research 7/2011 Naar de uitgave

OriginalPaper

Reliability and validity of the PedsQL™ Multidimensional Fatigue Scale in Japan

OriginalPaper

The World Health Organization Quality of Life Scale Brief Version: a validation study in patients with schizophrenia

OriginalPaper

Choosing appropriate patient-reported outcomes instrument for glaucoma research: a systematic review of vision instruments

OriginalPaper

The development of two postnatal health instruments: one for mothers (M-PHI) and one for fathers (F-PHI) to measure health during the first year of parenting

OriginalPaper

Health-related quality of life in adults reporting arthritis: analysis from the National Health Measurement Study

OriginalPaper

The development and validation of a general measure of well-being: the BBC well-being scale